R&D channel feed – Endpoints News

R&D channel feed

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

11 months ago

Lykos takes another hit as ICER lays out 'insufficient' evidence for MDMA-based treatment

11 months ago

To tackle a deadly brain disease, scientists devise small but charming epigenetic editing tool

11 months ago

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

11 months ago

Silence reports Phase 1 data from rare blood disorder trial

11 months ago

Q&A: Vertex’s pain research chief on moving beyond opioids, AI and how pharma acquisitions thrive or fail

11 months ago

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

11 months ago

Scientists unveil new way to make large changes to genes, and no CRISPR is required

11 months ago

Savara’s rare lung disease treatment passes Phase 3

11 months ago

Novo Nordisk takes $816M writedown after Phase 3 fail in chronic kidney disease

11 months ago

Moderna's updated RSV vaccine disappoints with only 50% efficacy

11 months ago

Zealand rides obesity wave with $1B raise to advance amylin drug and look for a partner

11 months ago

Lyell reports patient death, early responses in solid tumor CAR-T trial

11 months ago

Arrowhead shelves one cardiometabolic drug candidate, focuses on another

11 months ago

Lilly becomes the latest pharma to tap OpenAI for help, this time for antibiotic work

11 months ago

Can CRISPR be given twice? Small study from Intellia suggests it can

11 months ago

Wave Life Sciences touts Huntington's disease win in Phase 1b/2a trial

11 months ago

J&J's Tremfya fails giant cell arteritis study, where Roche and AbbVie have succeeded

11 months ago

AstraZeneca’s Imfinzi aces Phase 3 test in bladder cancer, fails another in lung cancer

11 months ago

Ex-Meta scientists launch EvolutionaryScale with $142M seed round, unveiling next-gen AI model for protein design

11 months ago

Merck KGaA's bet on head and neck cancer drug from Debiopharm ends in Phase 3 failure

11 months ago

Phase 3 breast cancer failure leads to staff cuts, stock drop at G1 Therapeutics

11 months ago

Novo reveals more hemophilia A data showing superiority in annualized bleeding rates

11 months ago

Gilead, Viking and Biohaven detail promising preclinical research in obesity and NASH

11 months ago

First page Previous page 38 39 404142 43 44 Next page Last page